This month, a paper reporting results from the LysoSENS project that SENS Foundation funds at Rice University will be published in the printed edition of Biotechnology and Bioengineering. (The paper is already available online.) The research that produced these results was primarily performed by Dr. Jacques Mathieu in the lab of Dr. Pedro Alvarez, in Rice University’s Department of Environmental Engineering. The project has focused on identifying enzymes that can degrade or modify 7-ketocholesterol (7KC) in the lysosomal environment. Because the cytotoxic effects of 7KC on the lysosomes of macrophages and foam cells are a root cause of atherosclerosis, such enzymes could ultimately be used in vivo as a new class of regenerative therapies to prevent and reverse heart disease.
The bacteria that express enzymes capable of degrading 7-KC, which is the objective of Lysosens. Lysosens is to remove junk that builds up in cells as a process of aging
Fightaging covers the progrss on Lysosens.
Given that many different harmful metabolic waste products exist, the field of biomedical remediation has enormous scope for growth – and certainly for more funding, which should hopefully start to arrive in the wake of proof of concept work like this. There is no need to slow down after finding one or more enzymes that break down 7-ketocholesterol, as firstly there could still be far better enzymes out there for this job, and secondly there remain numerous other damaging waste compounds in our cells and tissues that are worthy of biomedical remediation.
If you liked this article, please give it a quick review on ycombinator or StumbleUpon. Thanks
Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog Nextbigfuture.com is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.
Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.
A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts. He is open to public speaking and advising engagements.